For example, in the phase II FGF Initiating RevaScularization Trial (FIRST), a double-blind, randomized, and controlled study, a single intracoronary infusion of FGF2 was given to patients with severe coronary artery disease (Simons et al., 2002). The gene discussed is FGF2; the disease is coronary artery disorder.